Candida auris is a recently described pathogenic fungus that is causing invasive 24 outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-25 resistant strains that have been isolated in distinct sites across the globe. The fact that its 26 diagnosis is still problematic suggests that the spreading of the pathogen remains 27 underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance 28 employed by this new species are largely unknown. In the present work, we compared two 29 clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans 30 reference strain using a multi-omics approach. Our results show that, despite the distinct 31 drug-resistance profile, both C. auris strains appear to be very similar, albeit with a few 32 notable differences. However, when compared to C. albicans both C. auris strains have 33 major differences regarding their carbon utilization and downstream lipid and protein 34 content, suggesting a multi-factorial mechanism of drug resistance. The molecular profile 35 displayed by C. auris helps to explain the antifungal resistance and virulence phenotypes of 36 this new emerging pathogen.
Introduction 7 calibration, spectral deconvolution, and peak alignment were done with Metabolite 135 Detector (29). Metabolites were identified by matching against FiehnLib library (30) 136 containing additional metabolites entered in-house and/or the NIST14 GC-MS library. All 137 identified metabolites were manually inspected.
138
Quantitative analysis and data integration 139 Protein orthologues, lipids or metabolites were considered significantly different with a p-140 value ≤ 0.05 using T-test considering equal variance and two-tailed distribution. For 141 comparative analyses, missing values were zero-filled with half of the smallest value of the 142 dataset. Proteins were clustered by the k-means method using Multi-Experiment Viewer 143 (MeV v4.9.0) (31), which was also used to build the heatmaps. Pathway analysis on 144 different protein clusters was performed with DAVID (32), and specific pathways of 145 interested were manually inspected with Vanted v2.1.1 (33). We have recently developed 146 an R package called Rodin (https://github.com/PNNL-Comp-Mass-Spec/Rodin), to perform 147 structural 'lipid ontology' (LO) enrichment analysis. A web interface Lipid-MiniOn was 148 developed for non-R users (https://omicstools.pnnl.gov/shiny/lipid-mini-on/). Briefly, this 149 tool creates automatically LO bins based on the lipids naming and their inferred structure, 150 then it performs enrichment analysis using enrichment statistics to compare a Query list to 151 an Universe (Fisher's exact test, EASE score, Binomial test, or hypergeometric tests). In 152 this study a Fisher's exact test was used to perform the enrichment analysis and only the 153 enrichments with a Fisher's exact p value below 0.05 were considered to be conserved. As C. auris is a recently-identified pathogen, its breakpoints for resistance to different 157 antifungals have not been formally established. Given the lack of information, our results 158 were interpreted based on the CDC breakpoint suggestions 159 (https://www.cdc.gov/fungal/candida-auris/recommendations.html). MICs for the tested 160 strains against amphotericin B were similar, and all strains had a MIC below 2 μg/mL, thus 161 being susceptible against this antifungal. MMC2 was consider susceptible as the MIC to 162 caspofungin was below 2 μg/mL. MMC1 had a MIC of 2μg/mL for caspofungin, which 163 qualifies as resistance against this drug. Notably, C. auris strains were able to grow when 164 exposed to caspofungin concentrations above their MIC, a phenomenon known as 165 "Paradoxal effect" or "Eagle effect" (34). This effect was previously reported for 166 Aspergillus and Candida species (34), and was very recently described for C. auris (35) . C. 167 auris MMC2 was susceptible to fluconazole, presenting a MIC at 8 μg/mL. In contrast, C. 168 auris MMC1 strain was highly resistant as it was able to grow at concentrations of 1000 169 μg/mL of fluconazole (Table 1) . As a reference, we also examined a standard C. albicans 170 strain (ATCC #90028), which is susceptible to all the three drugs used in this work.
171
Proteomic profiling of C. auris vs. C. albicans 172 The proteomic analysis resulted in the identification of 1869 and 2317 proteins in C. auris 173 and C. albicans, respectively. To compare the data from these two species, we performed 174 BLAST searches and considered orthologous proteins with more than 40% similarity. Out 175 of the 1869 identified C. auris proteins, 1726 (92%) had orthologues in the C. albicans 176 genome, whereas 1954 of the 2317 (84%) C. albicans proteins had orthologues in the C. 177 auris genome. Combined, 2323 orthologues were detected in the proteomic analysis.
178
However, only 1357 (58% of total) orthologues were consistently abundant in both 9 Candida species (Table 2 and Supplemental Tables S1-S3 ). This indicates that despite the 180 sequence similarity between these two species their gene expression regulation is much 181 more divergent even in identical culturing conditions.
182
It is noteworthy that the peptides were not identical between the two species and, therefore, 183 a quantitative proteomic analysis comparison cannot be directly achieved across the 184 different samples. To circumvent these issues we performed an absolute quantification of 185 each protein using the intensity-based absolute quantification (iBAQ) method and 186 normalized each protein by a relative number of copies in the cells. The heatmap shown in 187 Figure 1 , depicts the orthologues that are differentially abundant between all three Candida 188 strains. Clustering these proteins using the k-means method showed a striking similarity 189 between the two C. auris isolates, but strong differences between the different species. To 190 better understand the differences between C. auris strains and the Candida species we 191 performed a function-enrichment analysis, which revealed that pathways such as 192 glycolysis/gluconeogenesis, ribosomes and phagosomes were more abundant in C. 193 albicans. On the other hand, C. auris seems to have a more active tricarboxylic acid (TCA) 194 cycle, along with lipid and amino acid metabolism.
195
Central carbon metabolism in C. auris and C. albicans 196 The pathway analysis showed that the glycolytic pathway was enriched in proteins with 197 higher abundance in C. albicans, whereas the TCA cycle proteins were enriched with 198 proteins more abundant in C. auris. Pyruvate metabolism was enriched in proteins that 199 were more abundant in both species (Figure 1 ). To validate these observations and to 200 correlate with downstream metabolic pathways, we integrated the proteomics data with a 201 metabolite analysis into a map of central carbon metabolism. Ten out of the fifteen 202 glycolysis/gluconeogenesis proteins were more abundant in C. albicans than in C. auris, 203 whereas only 2 proteins were consistently more abundant in C. auris (Figure 2 ). In 204 agreement with these observations, lactate, one of the end products of this pathway, was 16 205 fold more abundant in C. albicans than C. auris MMC1 and 6 fold higher than C. auris 206 MMC2 ( Figure 2 ). On the other hand, 14 out of 15 TCA cycle proteins were more abundant 207 in C. auris strains than in C. albicans (Figure 2 ). Validating these observations, citrate, and 208 fumarate had similar abundance profiles ( Figure 2 ). In the pyruvate metabolism, proteins 209 were not consistently more abundant in one or the other species. Some differentially 210 abundant proteins seemed to be due to gene isoforms that were preferentially expressed 211 between the species. For example, C. auris produces alcohol dehydrogenase Adh2, while 212 C. albicans produces Adh5 ( Figure 2 ). Unfortunately, the metabolites of this pathway, such 213 as acetate, acetaldehyde, and ethanol, are small and not detectable in our GC-MS analysis.
214
The fact that different proteins of this pathway are not uniformly more abundant in one of 215 the species makes it more difficult to predict whether the downstream metabolic pathways 216 would be affected. We decided to investigate the ergosterol and glycerolipids biosynthesis 217 pathways in more detail. (Figure 3 ). There are, however, a few exceptions of enzymes from the ergosterol 226 pathway that are more abundant in C. albicans than in C. auris, which is the case for Idi1 227 and Erg20. Farnesol, a quorum sensing molecule involved with C. albicans dimorphism is 228 poorly produced by both C. auris strains (Figure 3 ).
229
Lipid profile of C. auris and C. albicans 230 The differential abundance of carbon metabolism, especially in the pyruvate metabolism, is lysophospholipids is an indication of a higher phospholipase activity. We investigated the 247 abundance profiles of enzymes with phospholipase activity in the proteomics data (Table   248   12 3). Our analysis detected seven phospholipases in C. auris and only five in C. albicans. 249 Excepting Pld1 (A0A0L0P056), all of them were significantly more abundant in MMC1 Supplemental table S4 ).
260
Cell Wall Integrity (CWI) pathway, and major structural components. 261 The proteomic analysis showed that proteins involved in the cell wall integrity (CWI) 262 pathway displayed a significant difference between C. albicans and C. auris. Rom2, Tpk2, 263 and the MAP kinase Mck1 were higher in strain MMC1 when compared to C. albicans and 264 the fluconazole susceptible strain MMC2 ( Figure 6 ), suggesting that the MMC1 strain is 265 better suited to respond to antifungal drugs. Notably, the protein Pkc1 was detected only in 266 C. albicans, suggesting that C. auris may have an alternative pathway to control CWI 267 ( Figure 6 ).
268
The enzymes involved in the synthesis and degradation of the major cell wall 269 polysaccharides (glucans and chitin) and mannoproteins, were particularly distinct when C. Table S5 ). Out of 24 proteins previously reported upregulated in biofilm 285 (44), 8 were detected in higher levels in the C. auris strains when compared to C. albicans.
286

Transporters
287
The proteomic analysis identified 6 transporters related to drug resistance. Notably, the 288 ABC transporter efflux pump Cdr1 and orf19.4780, an uncharacterized member of the 289 Dha1 family of drug: proton drug antiporter, were significantly higher in the azole-resistant 290 strain MMC1 (Figure 7) . The other 4 transporters had higher abundance in other strains 291 (Figure 7) , therefore, they are less likely to be involved in the fluconazole resistance of 292 MMC1.
293
Discussion
294
C. auris is an emerging pathogen that is causing extremely worrisome outbreaks across the 295 globe. One remarkable feature of this fungus is the frequency of resistance against at least 296 one class of antifungals. In addition, multidrug-resistant strains have been isolated from all 297 continents. The search for a new class of antifungal drug has been a major challenge in the 298 medical mycology community and this quest becomes even more urgent with the spread of 299 a multidrug-resistant fungal organism like C. auris. In the current work, two strains of C. 300 auris isolated in the Bronx, USA were analyzed by a multi-omics approach in order to 301 better understand the molecular repertoire employed by this pathogen. In parallel to C. 302 auris, we also performed the same analyses with a reference strain of C. albicans. 303 We found that MMC2 and the C. albicans strain were susceptible to amphotericin B, which based on the CDC report, would make it a susceptible strain, even though the MIC 307 was about 10 times higher than for C. albicans. Although MMC1 just met resistance 308 criteria to caspofungin, its resistance to fluconazole was impressive, as even 1 mg/mL was 309 not able to totally inhibit growth. The "Eagle effect", also known as "paradoxical effect" 310 was observed in both C. auris strains after treatment with caspofungin, as growth occurred 311 at concentrations higher than the MIC. The protein profiles from C. auris and C. albicans were qualitatively and quantitatively 313 distinct, and both strains of C. auris presented very few differences from one another 314 (Supplemental Table S3 ). The major observed difference between C. auris and C. albicans 315 was in their central carbon metabolism. While proteins in the glycolysis pathway were 316 upregulated in C. albicans, C. auris showed an enrichment of proteins in the TCA cycle.
317
These results show that C. auris favors respiration, which is already known to be an 318 important mechanism of fluconazole resistance in C. albicans by increasing ATP 319 production and reducing oxidative stress, resulting in better overall fitness of the cell (45).
320
In S. cerevisiae, overexpression of HMG1 or deletion ERG2, can significantly increase 321 susceptibility to fluconazole, whereas deletion of HMG1, ERG6 and ERG3, as well as 322 overexpression of ERG11 are associated with fluconazole resistance (46). Therefore, we 323 integrated the data of proteins and metabolites of the ergosterol biosynthesis pathway. is due to modifications of multiple steps in the ergosterol biosynthesis pathway.
336
The lipids detected in C. auris were qualitatively similar to those found in C. albicans. 337 However, a quantitative analysis showed that C. albicans has more lipids involved with 338 energy storage, while C. auris has more structural glycerophospholipids and The response orchestrated by the CWI signaling pathway is central during cell wall and 359 membrane perturbation (55). Sensors at fungal cell surface initiate a downstream cascade in 360 order to adapt the cells under stress conditions controlling cell wall biogenesis and cell 361 integrity (55). Remarkably, we observed that the enzymes involved with cell wall 362 remodeling are reduced in both C. auris strains. However, some CWI proteins are 363 specifically higher in the resistant strain, suggesting that the response to external signals, 364 such as drug treatment, could be promptly controlled by the cell wall metabolism and help 365 to explain the resistant phenotype in the MMC1 strain.
366
The efflux of drugs mediated by efflux pumps is an important mechanism of antifungal 367 resistance employed by Candida spp (37, 56, 57) . From six distinct drug efflux transporters 368 produced by the analyzed organisms, two of them (Cdr1 and orf19.4780) were more 369 abundant in the fluconazole-resistant C. auris strain (MMC1) than in the other strains.
370
Previous publications showed that C. auris yeast cells, organized in a biofilm, are more 371 resistant to antifungals than planktonic cells and correlated this phenotype with the 372 increased expression of CDR1 (13). The impact of these efflux pumps is important during 373 early stages of biofilm formation but decreases when it becomes mature. In mature 374 biofilms, resistance is increased by the ability of matrix components to limit drug diffusion 375 along with the presence of persistent cells (58). Notably, the C. auris strain MMC1 has a 376 significant increase in proteins associated with biofilm formation and a higher abundance of 377 superoxide dismutase, an enzyme involved with reactive oxygen species (ROS) 378 detoxification and overexpressed in miconazole-tolerant persisters (58). Furthermore, a 379 18 number of proteins characterized in the biofilm matrix were also higher in the resistant C. 380 auris strain.
381
The comprehensive multi-omics approach used in this study has enabled us to begin to 382 uncover and characterize the molecular profile of the emerging pathogen C. auris, which 383 suggest a multifactorial mechanism of drug resistance in MMC1, including major 
